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Abstract
Fibroblast-mediated ex vivo gene therapy was evaluated in the N-acetylgalactosamine 4-sulfatase (4S) deficient
mucopolysaccharidosis type VI (MPS VI) cat. Skin biopsies were obtained at birth from severely affected MPS VI kittens and
used to initiate fibroblast outgrowths for retroviral transduction with the 4S cDNA. 4S gene expression in transduced cells
was under the transcriptional control of the MoMLV long terminal repeat promoter or the cytomegalovirus (CMV)
immediate^early promoter. Characterisation of gene-transduced fibroblasts demonstrated the cells to be over-expressing 4S
activity. Twenty-four to forty million autologous, gene-corrected fibroblasts were implanted under the renal capsule of three
MPS VI kittens at 8^16 weeks of age. Transient, low levels of 4S activity were detected in peripheral blood leukocytes shortly
after implantation but were not detectable within 3^8 weeks’ post-implantation. Long-term biochemical and clinical
evaluation of these cats demonstrated identical disease progression to that previously described in untreated, clinically severe
MPS VI cats. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Mucopolysaccharidosis type VI (MPS VI), also
known as Maroteaux^Lamy syndrome, occurs due
to a de¢ciency of the lysosomal hydrolase N-acetyl-
galactosamine 4-sulfatase (4S). A de¢ciency of 4S
leads to the lysosomal accumulation and urinary ex-
cretion of the glycosaminoglycan (GAG), dermatan
sulfate. A naturally occurring feline model for a se-
vere form of MPS VI has previously been described
[1] and a colony has been established in Adelaide to
study the progression of the disease and possible
therapies. We have previously identi¢ed a missense
mutation, L476P, which causes the clinically severe
form of feline MPS VI characteristic of the colony
and have developed a rapid polymerase chain reac-
tion (PCR)-based screening method to detect this
mutation [2,3]. The pathophysiology of feline and
human MPS VI is similar; both display progressive
skeletal disease, including epiphyseal abnormalities
of the long bones, rib deformities and spinal fusion.
Corneal clouding, soft tissue pathology and degener-
ative joint disease are also present in MPS VI cats
[4].
0925-4439 / 99 / $ ^ see front matter ß 1999 Elsevier Science B.V. All rights reserved.
PII: S 0 9 2 5 - 4 4 3 9 ( 9 8 ) 0 0 1 1 2 - 4
Abbreviations: MPS VI, mucopolysaccharidosis type VI; 4S,
N-acetylgalactosamine 4-sulfatase; f4S, feline 4S; rf4S, recombi-
nant f4S; rh4S, recombinant human 4S; GAG, glycosaminogly-
can; DS, dermatan sulfate; M6P, mannose-6-phosphate; 4MUS,
4-methylumbelliferyl sulfate; PBS, phosphate-bu¡ered saline
* Corresponding author. Fax: +61-8-204-7100.
BBADIS 61811 12-2-99
Biochimica et Biophysica Acta 1453 (1999) 284^296
The intravenous administration of recombinant
human 4S (rh4S) to severely a¡ected MPS VI cats
has been shown to dramatically reduce disease pro-
gression in a dose-dependent and age-dependent
manner [4^6]. An initial limited study suggested
that a reduction in disease progression appeared to
correlate with the earlier age of onset of therapy [4].
In a latter study in which rh4S replacement therapy
was initiated from birth (weekly, 1 mg/kg and 5 mg/
kg), there was near or complete normalisation of
dermatan sulfate storage in the heart valve, aorta,
skin, dura and liver, reduced spinal cord compres-
sion, increased body weight and a reduced urinary
GAG content [5]. Enzyme replacement therapy also
had a positive e¡ect on skeletal development in MPS
VI cats. Bone mineral volume and vertebral and tib-
ial bone length were improved in a dose-dependent
manner [6].
Although gene therapy is not used as a treatment
for the lysosomal storage disorders it is being devel-
oped in several MPS animal models including the
MPS VII mouse [7^9], MPS I dog [10], MPS IIID
goat [11] and MPS VI cat [12].
Skin ¢broblasts have a number of characteristics
which make them attractive for ex vivo mediated
gene therapy protocols. Firstly, ¢broblasts can be
easily isolated and cultured from small skin biopsies
and expanded to large numbers in cell culture. In the
case of MPS VI cats tail biopsies can be obtained
from a¡ected kittens within 1 week of birth and
used to initiate ¢broblast cultures. As the disease
progression of MPS VI is rapid and non-reversible,
it is imperative to initiate therapy protocols as soon
after birth as possible. For example, bone marrow
transplantation studies in the MPS VI cat have dem-
onstrated signi¢cant improvement in skeletal pathol-
ogy if performed before 4 months of age [13]. Sec-
ondly, due to their rapid growth in vitro ¢broblasts
can be readily transduced with retroviral vectors.
Gene-modi¢ed ¢broblasts can be implanted in vivo
using a variety of methods. The genetically modi¢ed
¢broblasts can be implanted subcutaneously [14^16]
or combined with collagen and synthetic ¢bres to
form retracted lattices termed ‘Neo-organs’, and im-
planted intraperitoneally [8,17^19]. A disadvantage
of using neo-organs for implanting gene corrected
¢broblasts is the loss of gene expression from im-
planted cells in vivo. The mechanism by which this
occurs has not been determined. However, some
groups have reported a rapid in¢ltration of colonis-
ing immune cells and host ¢broblasts into the im-
planted neo-organ [19].
In this study we investigated an alternative site for
implanting gene-corrected ¢broblasts; the sub-capsu-
lar space under the renal capsule. The renal capsule
has a number of advantages which make it an attrac-
tive site for the implantation of autologous gene-cor-
rected ¢broblasts. Firstly, the renal capsule and the
underlying kidney tissue is primarily composed of
¢broblasts. Thus, the natural cavity beneath the re-
nal capsule may be a receptive site for the implanta-
tion of autologous gene-corrected ¢broblasts. Sec-
ondly, the renal capsule may act as a natural
barrier and prevent the loss of implanted cells in
vivo. Finally, as the kidney is extensively vascularised
it is likely that therapeutic enzyme secreted from
gene-corrected ¢broblasts will enter the systemic cir-
culation and distribute to the various somatic sites of
pathology in the MPS VI cat. In mice, genetically
engineered skin ¢broblasts which over-express re-
combinant human growth hormone (hGH), have
been successfully implanted under the renal capsule.
These implanted cells become vascularised within
one week of implantation and result in circulating
levels of hGH being detected for the lifetime of the
animal [20].
The aim of this study was to implant autologous
4S gene-transduced ¢broblasts under the renal cap-
sule of MPS VI kittens and determine the extent of
resulting enzyme replacement and its e¡ect upon dis-
ease progression.
2. Materials and methods
The MPS VI cat colony was established in 1984
from ‘Family 3’ heterozygous cats [1] kindly obtained
from Professor Mark Haskins (School of Veterinary
Medicine, University of Pennsylvania, Philadelphia,
PA, USA) and housed at the Institute of Medical
and Veterinary Science ¢eld station at Gilles Plains,
Adelaide. The genotypes of kittens was determined at
birth using a rapid PCR-based screening method
which has been described previously [2,3].
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2.1. Isolation and culture of feline MPS VI skin
¢broblasts
Five severely a¡ected L476P homozygous cats
were used in these experiments. Within seven days
of birth, a 0.5 cm tail tip was cut from each kitten.
The tail biopsies were incubated in 20 ml Dulbecco’s
modi¢ed Eagle’s medium (DMEM) supplemented
with 10% (v/v) foetal calf serum (FCS), antibiotics
and fungizone at room temperature overnight.
Each tail biopsy was then minced into small pieces
and incubated with fresh medium supplemented with
10% (v/v) FCS, antibiotics and fungizone at 37‡C for
1^2 h. Tissue pieces were then transferred to the
growth surface of a 75-cm2 tissue culture £ask and
left to adhere for approximately 1 h without any
medium. Three ml of DMEM supplemented with
10% FCS and antibiotics was then added to each
£ask. Every 2^3 days an additional 2 ml of growth
medium was added to each £ask. Within 10 days,
sheets of ¢broblasts had grown out from most tissue
pieces. Fibroblasts were harvested with PBS contain-
ing 10% trypsin (v/v) and transferred to a new tissue
culture £ask. From then on ¢broblasts were subcul-
tured 1:2 weekly in DMEM containing 10% (v/v)
FCS.
2.2. Retrovirus packaging cell lines
The PA317/Lf4S and PA317/LNC4S virus pack-
aging cell lines have been previously described
[12,21].
2.3. Retroviral transduction of feline skin ¢broblasts
When expanded to a 75 cm2 £ask (50% con£uent),
skin ¢broblasts were exposed to seven cycles of
transduction with freshly harvested PA317/Lf4S vi-
rus or PA317/LNC4S virus (see Table 1). Brie£y,
each virus packaging cell line was grown to con£u-
ence in 75-cm2 £asks and then conditioned with 7 ml
of fresh medium for 16^24 h. Virus-containing me-
dium was then harvested, ¢ltered (0.22 Wm ¢lter),
combined with 3 ml fresh medium and polybrene
(4 Wg/ml ¢nal concentration) and placed on target
cells. Each virus exposure was approximately 16^24
h. During the virus transduction period (approxi-
mately 7 days) the transduced skin ¢broblasts were
subcultured into two 75-cm2 £asks and then four 75-
cm2 £asks. Following the ¢nal exposure to virus,
¢broblasts were expanded to 36 tissue culture £asks
(75 cm2). Stocks of each retrovirus-transduced skin
¢broblast line were frozen down in DMEM contain-
ing 10% (v/v) FCS and 10% (v/v) DMSO (Sigma)
and used later for determination of 4S activity and
Southern blot analysis (see below).
2.4. Southern blot analysis
High molecular mass DNA was prepared from
transduced ¢broblasts as described previously [12].
Ten micrograms of each DNA preparation was di-
gested with 30 units of KpnI restriction enzyme at
37‡C for 24 h. Digested DNA was electrophoresed
through a 1% agarose gel in 1UTAE bu¡er, trans-
ferred onto Genescreen Plus membranes and probed
with an [K32P]dATP-labelled 279 bp DNA fragment
corresponding to exon 1 of the feline 4S gene [2].
Filters were washed in 0.2USSC, 0.1% (w/v) SDS
at 65‡C for 30 min and then exposed to ¢lm.
2.5. Preparation of ¢brin ‘glue’
The glue was prepared as two separate compo-
nents: autologous ¢brinogen substrate and throm-
bin. The two solutions were maintained in separate
syringes and transported to the cat colony. Combin-
ing the solutions over the injection site of the renal
capsule caused the ¢brinogen to clot and form a
¢brin glue over the injection area. Both solutions
were freshly prepared on the day of implantation
as follows.
Approximately 2^5 ml blood was collected from
cats prior to the implantation of autologous ¢bro-
blasts under the renal capsule. The blood was imme-
diately combined with a 0.1 volume of sterile 3.8%
sodium citrate and the autologous ¢brin was pre-
pared [22]. Brie£y, the blood/sodium citrate mixture
was centrifuged at 2000Ug for 12 min. The plasma
was removed and combined with 0.25 volumes of
sterile super-saturated ammonium sulfate (71 g/100
ml H2O at room temperature). The precipitated ¢-
brinogen was then recovered by centrifugation at
2000Ug for 3 min and resuspended in a 0.1 volume
of sterile 0.025 M CaCl2.
5000 U of topical thrombin was dissolved in 8.2 ml
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of sterile 0.025 M CaCl2 and then combined with 100
Wl of Ekaprol (aminocaproic acid, an inhibitor of
¢brin breakdown, 250 mg/ml).
2.6. Implantation of autologous gene-transduced
¢broblasts under the renal capsule
Virus-transduced ¢broblasts were harvested (with
100 ml PBS containing 10% (v/v) trypsin^versene),
combined with FCS (10 ml) to inactivate the trypsin,
washed with six 100-ml volumes of PBS, resuspended
in 0.55 ml^1 ml of PBS and transported to the cat
colony at room temperature. General anaesthesia
was induced in all cats with halothane. A mid-line
incision in the lower abdominal region was made and
the ventral aspect of the left kidney carefully ex-
posed. Autologous gene-transduced skin ¢broblasts
were injected under the renal capsule on the ventral
side. The needle tip (23 gauge) was inserted under the
outer ¢brous renal capsule approximately 1 cm away
from the penetration point before the cells were ex-
pelled. The injected cells appeared to spread a small
distance from the injection site under the semi-trans-
parent renal capsule. No cell leakage or bleeding
occurred during the injection. To prevent cell leakage
upon removal of the needle, a few drops of autolo-
gous ¢brin and thrombin were placed over the needle
penetration area while the needle was still in place.
Clotting occurred within 30 s at which time the nee-
dle was slowly removed. The kidney was then gently
placed back into the abdominal cavity. In some in-
stances, the right kidney was also injected with au-
tologous, gene-transduced skin ¢broblasts. The mid-
line incision was then sutured and the Halothane
slowly reduced. Cats 241, 244 and 246 were admin-
istered antihistamines prior to surgery and pethidine
immediately after the surgery. The duration of sur-
gery was usually 40 min^1 h. Recovery time was
approximately 30^60 min.
2.7. Isolation of plasma and leukocytes from feline
blood
Approximately 3 ml of venous blood was collected
from cats in lithium heparin tubes. Leukocytes were
isolated within 8 h using the dextran sedimentation
method [23] followed by hypotonic saline washes to
remove remaining red blood cells. Brie£y, the blood
was centrifuged at 1500Ug (3000 rpm) for 5 min and
the plasma removed and immediately stored at
320‡C. The cell pellet was gently resuspended in
one original volume of 0.9% (w/v) NaCl and one
volume of dextran^saline solution (5% (w/v) dextran,
0.7% (w/v) NaCl in H2O). The blood mixture was
left to stand at room temperature for 10^15 min or
until the red blood cells had sedimented to the lower
one-third of the tube. The leukocyte containing
supernatant was transferred to a fresh tube and pel-
leted at 750Ug (2500 rpm). The cell pellet was resus-
pended in 2 ml of 0.2% NaCl with a plastic transfer
pipette and left for exactly 45 s, then combined with
1.6 ml of 1.8% NaCl. The cells were then divided
between two eppendorfs and pelleted at 750Ug.
The supernatant which contained lysed red blood
cells was completely removed. If the cell pellets
were still red in colour, the lysis procedure was re-
peated with 0.2% NaCl. The cell pellets were imme-
diately stored at 380‡C.
2.8. Semi-quantitative analysis of urinary
mucopolysaccharides using alcian blue
Urine samples were collected by manual bladder
expression with xylazine sedation (1^2 mg/kg subcu-
taneously) or general anaesthesia while undergoing
radiological procedures. Samples were stored without
preservative at 320‡C until assayed. Total urine gly-
cosaminoglycan (GAG) content was quantitated us-
ing a modi¢ed alcian blue spectrophotometric meth-
od [24]. Brie£y, alcian blue 8GX (20 mg) was
dissolved in 10 ml of 0.5 M sodium acetate bu¡er
(pH 5.8) and clari¢ed by centrifugation at 1500Ug
for 10 min. Urine samples were defrosted at room
temperature and then diluted 1/8 in 0.5 M sodium
acetate bu¡er, pH 5.8. Each diluted urine sample
(250 Wl) was combined with 625 Wl of freshly pre-
pared dye reagent or 625 Wl of 0.5 M sodium acetate
bu¡er (test blank), left for 30 min at room temper-
ature and the absorbance measured at 480 nm.
Standards which contained 250 Wl of 25, 50, 75,
100, 200, 300 or 400 mg/l of chondroitin 4-sulfate
type A (Sigma, product # C4134) were also com-
bined with the dye reagent. The reading obtained
for each sample was subtracted from the correspond-
ing test blank and the result extrapolated through the
chondroitin 4-sulfate standard curve to determine the
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MPS content (mg/l). Urine creatinine was quanti-
tated (mmol/l) using an autoanalyser method (Beck-
man Sychron CX Systems). The concentration of
urinary GAG in each sample was expressed as g/
mol creatinine.
2.9. Western blot analysis of rf4S with cat 241, 244
and 246 plasma
Recombinant f4S (4 Wg/lane) was electrophoresed
through a 12% mini SDS^PAGE gel and then elec-
troblotted onto nitrocellulose. The blot was cut into
strips containing one lane of pre-stained standards
(Bio-Rad) and one lane of rf4S. Non-speci¢c protein
binding sites on the nitrocellulose were saturated by
incubating the membrane in 20 mM Tris, 150 mM
NaCl (TBS; pH 8.0) containing 5% (w/v) BSA for 2 h
at room temperature. Each strip was washed with
TBS and then incubated with feline plasma diluted
1/2 in antibody dilution bu¡er (TBS containing 0.1%
(v/v) Tween-20 and 2% (w/v) BSA). As a negative
control and positive control, nitrocellulose strips
containing rf4S were incubated with FCS or rabbit
Krf4S polyclonal serum, respectively (diluted 1/2 in
antibody dilution bu¡er). Plasma from an untreated
normal cat and an untreated MPS VI cat were also
used as additional controls. The nitrocellulose strips
were incubated with feline plasma or control plasma
overnight at room temperature. The strips were then
individually washed with TBS and incubated with a
peroxidase-conjugated a⁄nity puri¢ed goat K-cat
IgG (H+L) (ImmunResearch Laboratories; 1/1000
dilution in antibody dilution bu¡er) or a HRP-con-
jugated sheep anti-rabbit IgG (positive control strip;
1/1000 dilution) for 1 h at room temperature. After
washing individually with TBS, each strip was devel-
oped using 4-chloro-1-naphthol substrate (Sigma; 60
mg dissolved in 20 ml ice-cold methanol and then
combined with 100 ml 0.02 M Tris, 0.25 M NaCl
and 60 Wl hydrogen peroxide). Development was
stopped by rinsing the membrane with several
changes of water. To permit comparison, all blots
were developed for the same length of time.
2.10. Preparation of cell lysates
Leukocyte lysates were prepared by seven cycles of
freeze^thaw in 0.1% (v/v) Triton X-100. Cultured
skin ¢broblasts were harvested with PBS containing
trypsin^versene (Gibco-BRL) and washed with PBS.
Cell lysates were prepared by seven cycles of freeze^
thaw in 0.5 M NaCl, 20 mM Tris^HCl, pH 7.
Growth medium and cell lysates were clari¢ed by
centrifugation. Total cellular protein was quanti¢ed
using the Bio-Rad protein assay. L-Hexosaminidase
activity was determined by using the £uorogenic sub-
strate, 4-methylumbelliferyl-2-acetamido-2-deoxy-L-
D-glucopyranoside [25]. Once prepared, cell lysates
were kept on ice at all times.
2.11. Determination of 4S activity
Fibroblast lysates were assayed for total arylsulfa-
tase activity using the £uorogenic substrate, 4MUS
[26]. Leukocyte lysates were dialysed for 16 h against
50 mM sodium formate (pH 3.5), and then speci¢-
cally assayed for 4S by incubation with the radiola-
belled trisaccharide substrate GalNAc4S^GlcA^Gali-
Table 1
Summary of the exposures of feline ¢broblasts to Lf4S or LNC4S retrovirus and the number of population doublings prior to implan-
tation, the total number of autologous cells implanted, and cat ages and body weights at the time of ¢broblast implantation
Cat Virus
construct
Secreted 4S
(Wg per 24 h)
No. of
doublings
Total no.
of cells
implanted
Age at
implantation
(weeks)
Weight at
implantation
(kg)
Cell
dose
per kg
Survived
surgery
Mo 205 Lf4S n.d. 4 1.26U108 5 0.610 2.07U108 No
Mo 199S LNC4S n.d. 5 1.50U108 5 0.873 1.72U108 No
241 Lf4S 25.65 12 4.05U107 16 1.619 2.50U107 Yes
244 LNC4S 80.55 4 3.24U107 11 1.400 2.30U107 Yes
246 LNC4S 28.84 7 2.40U107 8 1.107 2.20U107 Yes
The total amount of secreted 4S protein was determined by assaying 24-h conditioned medium from each ¢broblast line with the £uo-
rogenic substrate, 4MUS. n.d., Not determined.
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tolNAc4S for 18 h [27]. Cat tissue extracts were pre-
pared and assayed for 4S activity towards the trisac-
charide substrate as previously described [4].
3. Results
3.1. Characterisation of 4S gene-transduced
¢broblasts prior to implantation
Fibroblasts were isolated from ¢ve MPS VI kittens
and transduced with either PA317/Lf4S or PA317/
LNC4S virus as indicated in Table 1. Fibroblasts
transduced with LNC4S sequence were selected
with G418. Following the ¢nal transduction with vi-
rus, ¢broblasts were passaged for varying times.
Generally, after 4^5 doublings su⁄cient numbers of
gene-corrected cells (3.24U107^1.25U108) were ob-
tained for implantation under the renal capsule (Ta-
ble 1). Cat 241 ¢broblasts transduced with Lf4S were
subcultured 12 times before implantation (Table 1)
as prior to this it was not possible to implant 241
gene-corrected ¢broblasts for logistical reasons.
Southern blot analysis was performed to determine
the level of 4S gene transduction in cat 241, 244 and
246 ¢broblasts. The probe used was a 279 bp DNA
fragment corresponding to exon 1 of the feline 4S
gene [12]. The viral long terminal repeat (LTR) se-
quences of the Lf4S and LNC4S virus constructs
contain KpnI restriction sites, enabling excision of
the proviral sequences from genomic DNA [12,21].
Southern blot analysis of KpnI digested genomic
DNA showed that proviral sequence was present in
Lf4S-transduced 241 ¢broblasts, LNC4S-transduced
244 ¢broblasts and LNC4S-transduced 246 ¢bro-
blasts, respectively (Fig. 1). To quantify Lf4S and
LNC4S transduction in 241, 244 and 246 ¢broblasts,
the intensity of the endogenous diploid 4S band in
each lane of Fig. 1 was compared with the intensity
of the corresponding provirus band via densitometric
analysis. Quanti¢cation of these results by densitom-
etry gave transduction frequencies of 0.4, 2.3 and 1.4
proviral copies per cell for Lf4S/241, LNC4S/244 and
LNC4S/246 gene-transduced ¢broblasts, respectively.
Levels of intracellular total arylsulfatase activity in
Lf4S/241, LNC4S/244 and LNC4S/246 gene-trans-
duced ¢broblasts were shown to be elevated 14-
fold, 44-fold and 26-fold, respectively, when com-
pared with normal ¢broblast levels (Table 2). Con-
trol feline MPS VI ¢broblasts which are de¢cient in
arylsulfatase B activity (4S) and had not been ex-
posed to retrovirus contained very low levels of total
arylsulfatase activity (0.08 nmol/min per mg, Table
2). We have therefore made the assumption that the
majority of total arylsulfatase activity detected in
241, 244 and 246 4S gene-transduced ¢broblasts cor-
responds to arylsulfatase B.
To demonstrate that the rf4S enzyme over-ex-
pressed by 4S gene-transduced ¢broblasts was being
correctly processed and secreted into the culture me-
dium, MPS VI ¢broblasts were incubated with 24 h
conditioned medium harvested from either Lf4S-
transduced 241 ¢broblasts, LNC4S-transduced 244
¢broblasts or LNC4S-transduced 246 ¢broblasts. In-
cubation with conditioned medium from these 4S
gene-transduced ¢broblasts resulted in the detection
of above normal intracellular 4S activity levels in
Fig. 1. Southern blot analysis of 4S gene-transduced cat 241,
244 and 246 ¢broblasts. High molecular mass DNA isolated
from Lf4S-transduced 241 ¢broblasts, LNC4S-transduced 244
¢broblasts and LNC4S-transduced 246 ¢broblasts was digested
with KpnI restriction enzyme and probed for f4S DNA se-
quence. Feline diploid 4S gene sequence also hybridised to the
f4S cDNA probe and were used to control for DNA loading.
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MPS VI ¢broblasts (Table 2). Twenty-four-hour con-
ditioned medium was harvested from con£uent 4S
gene-transduced 241, 244 and 246 ¢broblasts prior
to implantation and assayed for total arylsulfatase
activity using 4MUS. The amount of 4S activity se-
creted by the total number of cells implanted into
each cat was calculated and used to determine the
approximate levels of 4S protein secreted from these
cells over a 24-h period. Based on a speci¢c activity
of 20 000 nmol/min per mg for immunopuri¢ed 4S
against 4MUS (J. Bielicki, personal communication),
we calculated that the total number of implanted 4S
gene-transduced 241, 244 and 246 ¢broblasts secreted
approximately 26 Wg, 80 Wg and 29 Wg, respectively,
of 4S every 24 h into the culture medium (Table 1).
3.2. Mortality associated with cell implantation
Autologous ¢broblasts were harvested, resus-
pended in PBS and surgically implanted under the
renal capsule as described in Section 2. After inject-
ing autologous, gene-transduced ¢broblasts under
the left renal capsule, cat Mo 205 and cat Mo 199
stopped breathing. Attempts to revive both cats were
unsuccessful. Signi¢cant pulmonary congestion and
oedema in the heart and lungs of cat Mo 199 were
observed at postmortem (R. Reuter, personal com-
munication). The presence of thrombi in many ves-
sels of the lung and in the coronary arteries sug-
gested intravascular coagulation may have been
involved in the death of the animal. The exact cause
of death in these cats was not determined. However,
both cats were 5 weeks of age, weighed less than 0.9
kg and were implanted with high concentrations of
cells (Table 1).
The remaining MPS VI cats evaluated in this study
were injected with less concentrated doses of autolo-
gous, 4S gene-transduced ¢broblasts at an older age
(Table 1). Cat 241, cat 244 and cat 246 weighed 1.619
kg, 1.4 kg and 1.107 kg, respectively, and were all 7
weeks or older at the time of implantation (Table 1).
All cats tolerated the surgery although a slight de-
crease in heart rate was observed during the injection
of cells under the renal capsule.
3.3. Long-term biochemical assessment of cats 241,
244 and 246 following implantation of 4S
gene-transduced ¢broblasts
A blood and urine sample was collected a few
hours before the implantation of autologous cells.
Blood and urine samples were also obtained from
cats 241, 244 and 246 at regular intervals following
implantation of 4S gene-transduced ¢broblasts. Leu-
kocytes and plasma were isolated from blood as de-
scribed in Section 2.
3.3.1. Leukocyte 4S activity levels
Leukocytes isolated from cats before and after im-
plantation of gene-corrected cells were assayed for 4S
Table 2
Characterisation of 241, 244 and 246 transduced ¢broblasts prior to implantation
Total arylsulfatase
(nmol/min/mg cell protein)
L-Hexosaminidase
(nmol/min/mg cell protein)
Normal ¢broblasts 0.62 þ 0.08 88.54 þ 9.54
MPS VI ¢broblasts 0.08 þ 0.006 65.48 þ 4.17
241/Lf4S 8.62 þ 0.18 86.39 þ 5.26
244/LNC4S 27.5 þ 1.7 69.27 þ 2.82
246/LNC4S 15.9 þ 7.7* 35.96 þ 1.15a
MPS VI ¢broblasts+241/Lf4S medium 0.91 þ 0.04 62.00 þ 8.27
MPS VI ¢broblasts+244/LNC4S medium 6.82 þ 1.3 58.33 þ 4.89
MPS VI ¢broblasts+246/LNC4S medium 0.89 þ 0.05 63.10 þ 2.70
Control normal and MPS VI (L476P homozygous) ¢broblasts and 241/Lf4S, 244/LNC4S and 246/LNC4S virus-transduced ¢broblasts
were grown to con£uence in 25-cm2 culture £asks (rows 1^5, respectively). Cell lysates were prepared and assayed for total arylsulfa-
tase activity using 4MUS and L-hexosaminidase activity. Three groups of MPS VI ¢broblasts (L476P homozygous) were also incu-
bated with 241/Lf4S, 244/LNC4S or 246/LNC4S 24-h conditioned medium for 48 h prior to being harvested and assayed for total ar-
ylsulfatase and L-hexosaminidase (rows 6^8, respectively). Results are expressed as the mean þ standard error (n = 3).
an = 2.
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activity using the trisaccharide substrate (see Section
2). Cats 241, 244 and 246 contained transient, low
levels of 4S activity in their leukocytes in the ¢rst 3^8
weeks after implantation of ¢broblasts (Fig. 2).
Blood was collected from Cat 246 10 min after im-
plantation of the autologous LNC4S-transduced ¢-
broblasts. Leukocytes isolated from this sample con-
tained readily detectable 4S activity (Fig. 2). This 4S
activity may represent 4S enzyme released from im-
planted, lysed cells or alternatively may represent a
small number of LNC4S transduced ¢broblasts
which entered the systemic circulation during im-
plantation and were puri¢ed along with the leuko-
cytes in the blood sample (Fig. 2). At the time of
death, no 4S activity was detected in kidney, liver
or spleen tissues in any of the three animals (data
not shown).
3.3.2. Urinary MPS levels
The total GAG content in the urine of cats 241,
244 and 246 was similar to that of an untreated MPS
VI cat (cat 222) for the duration of the experiment.
In comparison, cat 248 (a normal, untreated cat)
contained signi¢cantly lower levels of urinary GAG
(Result not shown).
3.3.3. Identi¢cation of low-titre antibody reactivity to
rf4S
Western blot analysis demonstrated the presence
of low-titre, pre-existing antibodies against rf4S in
plasma obtained from untreated normal and MPS
VI cats and cats 241, 244 and 246 before and after
implantation of cells (results not shown). However,
there was no evidence for an increase in antibody
titre following the implantation of autologous, 4S
gene-transduced ¢broblasts under the renal capsule.
The presence of pre-existing, low-titre rf4S antibodies
in untreated normal and MPS VI cats has been pre-
viously described [28]. One likely explanation for
their presence may be a speci¢city towards a second,
Fig. 2. 4S activity levels in cat 241, 244 and 246 peripheral
blood leukocytes. Leukocytes were isolated from blood samples
collected before and after implantation of 4S gene-transduced
¢broblasts and assayed for L-hexosaminidase activity or 4S ac-
tivity using the trisaccharide substrate. Results are expressed as
a ratio of 4S activity to L-hexosaminidase activity.
6
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unknown antigen. Such antibodies may cross-
react with low speci¢city towards an epitope on 4S
[28].
3.4. Clinical assessment of disease progression in cats
undergoing 4S gene therapy
3.4.1. Gross pathology
Cats 241, 244 and 246 were killed at 8.5 months,
10 months and 8 months, respectively, using an over-
dose of IV barbiturate. Gross pathology in cats 241,
244 and 246 was identical to the characteristic fea-
tures of untreated MPS VI cats in the colony [4].
3.4.2. Radiological assessment
Radiological examination under general anaesthe-
sia was performed on cats 241, 244 and 246 at
3 months, 5 months, 6 months and 10 months (cat
244 only) as described previously [5]. Progression of
skeletal pathology in cats 241, 244 and 246 was no
di¡erent from that observed in age-matched un-
treated MPS VI control cats [5,29].
3.4.3. Hind-limb neurological de¢cits
In cats 241 and 246, complete hind-limb paralysis
due to spinal cord compression was evident by
5 months. By 6 months of age approximately 60%
of untreated MPS VI cats in the colony displayed
permanent hind-limb neurological de¢cits [4]. Cat
244 did not appear to develop any neurological
de¢cits, although gait and mobility were altered
due to progressive skeletal disease. At 10 months
(just prior to euthanasia), cat 244 was usually seden-
tary and inactive but was still able to walk.
3.4.4. Electron microscopy (EM)
At euthanasia, underlying kidney tissue and the
renal capsule area corresponding to where the autol-
ogous cells were implanted was removed, placed in
EM ¢x and immediately processed as described pre-
viously [4]. Analysis of both kidneys from each cat
revealed no di¡erences in lysosomal storage when
compared with kidney tissue from untreated MPS
VI cats. In addition, liver, spleen and lymph node
(cat 244 only) tissue were analysed via EM and com-
pared with tissue samples from age-matched, un-
treated MPS VI cats. No di¡erence in lysosomal
vacuolation was observed in tissues from cats 241,
244 and 246 when compared with tissues from un-
treated, age-matched control MPS VI cats.
4. Discussion
A generally applicable gene therapy treatment for
the MPS must be able to deliver signi¢cant amounts
of mannose-6-phosphorylated recombinant enzyme
to a large number of sites in the body. Many gene
therapy strategies are based on the genetic modi¢ca-
tion of cells that can be readily isolated, cultured,
modi¢ed and re-implanted such as ¢broblasts and
myoblasts. Recombinant enzyme secreted from such
implanted gene-corrected cells can then enter the sys-
temic circulation and so distribute to the various
somatic sites of pathology found in the MPS disor-
ders. However, such a strategy may not be e¡ective
in those MPS in which there is CNS involvement,
due to the presence of the blood^brain barrier. Sys-
temic gene therapy protocols may therefore be re-
stricted to those MPS in which there is no CNS in-
volvement, such as types IVA and VI, or in the less
severe forms of other MPS in which CNS involve-
ment is minimal or absent.
The MPS VI cat is an excellent large animal model
to evaluate therapy protocols. Because there is no
CNS involvement in MPS VI, there is no require-
ment for the therapeutic protein to cross the
blood^brain barrier, thereby enabling most somatic
sites of pathology to be potentially accessible to cir-
culating enzyme. Furthermore, the MPS VI cat dis-
plays similar disease progression to the severe form
of human MPS VI [1] and as these cats contain low
levels of mutant enzyme [2] they are likely to be
immunologically tolerant to f4S in successful gene
therapy protocols.
In this study, 4S gene-transduced skin ¢broblasts
were implanted under the renal capsule of MPS VI
cats. This method was initially developed in nude
mice and involved implanting clonal populations of
rabbit ¢broblasts expressing human growth hormone
under the renal capsule [20]. The implantation of
these ¢broblasts induced vascularisation of the kid-
ney. Sustained, low levels of human growth hormone
(1^4 ng/ml) were detected in the serum for the life
time of the experimental animals [20].
Two retroviral constructs that transduce the 4S
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gene, pLf4S and pLNC4S, were used to transduce
feline MPS VI skin ¢broblasts. In the simpli¢ed
pLf4S construct the f4S cDNA is under the tran-
scriptional control of the viral long terminal repeat
(LTR) promoter. Amphotropic virus produced from
the pLf4S construct has previously been used to
transduce feline MPS VI myoblasts resulting in
over-expression of f4S activity and correction of
GAG storage [12]. In the pLNC4S retroviral con-
struct the human 4S cDNA is under the transcrip-
tional control of the internal cytomegalovirus (CMV)
immediate^early promoter. LNC4S has previously
been used to express high levels of 4S in primary
cultures of human MPS VI ¢broblasts [21]. It was
anticipated that both the pLf4S and pLNC4S retro-
viral constructs would work well in feline MPS VI
skin ¢broblasts.
Following retroviral-mediated 4S gene transfer, cat
241, cat 244 and cat 246 ¢broblasts expressed ele-
vated levels of 4S activity (14-fold, 44-fold and 26-
fold elevated levels of 4S activity when compared
with normal cat ¢broblasts, Table 2). The potential
for systemic correction of the feline MPS VI pheno-
type was demonstrated in this study by the over-ex-
pression and secretion of 4S in Lf4S-transduced 241
¢broblasts and LNC4S-transduced 244 and 246 ¢-
broblasts. Recombinant 4S secreted from these cells
was capable of being endocytosed by a second pop-
ulation of MPS VI skin ¢broblasts, resulting in intra-
cellular arylsulfatase activity levels above those
found in normal control ¢broblasts (Table 2). The
amount of 4S activity secreted per day by the total
number of implanted 4S gene-transduced 241, 244
and 246 ¢broblasts was approximately 26 Wg, 80 Wg
and 29 Wg, respectively (Table 1). These cells there-
fore had the potential to secrete 182^560 Wg of 4S per
week into the peripheral circulation of MPS VI kit-
tens. As a comparison, an intravenous dose of 4S (1
mg/kg) for enzyme replacement therapy in the MPS
VI cat (administered weekly as a bolus dose) results
in signi¢cantly reduced disease progression and nor-
malisation of GAG storage in the heart valve, aorta,
skin, dura and liver (results in [5]).
In this study only transient, low levels of 4S activ-
ity were detected in peripheral blood leukocytes from
cats 241, 244 and 246 shortly after implantation of
autologous, gene-corrected ¢broblasts but were no
longer detectable after 3^8 weeks post-implantation.
Furthermore, in contrast to the results obtained by
Heartlein et al. [20], the implantation of 4S gene-
transduced ¢broblasts under the renal capsule did
not induce extra vascularisation of the kidney in
MPS VI cats. The biochemical parameters (4S activ-
ity levels, DSuria) and clinical parameters (gross
pathology and radiological assessment) which were
used to evaluate disease progression in these cats
demonstrated no changes in disease progression
when compared with age-matched control MPS VI
cats. Collectively, these results suggest that ¢bro-
blast-mediated gene transfer did not improve the
clinical symptoms associated with severe MPS VI.
The causative factors which led to a loss of 4S
expression from implanted genetically modi¢ed ¢bro-
blasts in MPS VI cats was not determined. The im-
plantation of cells into the con¢ned subcapsular
space of the kidney may have resulted in many of
the cells having no access to nutrients, which in turn
may have led to cell death or migration of cells into
the peripheral kidney tissue where abundant extra-
cellular matrix and nutrients are present.
In addition, it is now also clear that re-implanted
¢broblasts have a limited in vivo life span which is
dependent upon the proliferative potential of the
cells [30]. Over the course of the transduction/expan-
sion protocol, ¢broblast cell volume increased, satu-
ration density decreased and doubling time in-
creased, all characteristic of untransformed,
senescing cells [31]. At the time of implantation, au-
tologous ¢broblasts were very large and elongated in
appearance. Apoptosis of ‘older’, senescent ¢bro-
blasts may therefore be responsible for the reduced
levels of therapeutic gene expression observed from
implanted feline 4S gene-transduced ¢broblasts in
cats 241, 244 and 246 and implanted ¢broblasts in
other ex vivo gene therapy experiments [8,15,18,32].
Another factor contributing to the loss of detect-
able 4S activity in cats 241, 244 and 246 is likely to
be down-regulation of 4S gene expression in the im-
planted ¢broblasts. Studies with ¢broblasts have
demonstrated that the choice of promoter used to
drive therapeutic gene expression is a major determi-
nant for long-term expression in vivo. Long-term
expression of the L-galactosidase reporter gene in
retrovirally transduced mouse embryo ¢broblasts
was only observed in vivo when reporter gene expres-
sion was under the transcriptional control of the
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housekeeping dihydrofolate reductase (DHFR) gene
promoter and not the CMV promoter [32]. Similar in
vivo studies have been observed with other viral pro-
moters in primary ¢broblasts. For example, Palmer
et al. [14] demonstrated the CMV, SV40 and Mo-
MLV LTR promoters to be expressed well in ¢bro-
blast in vitro, but attenuated upon returning the cells
to animals in the absence of cellular or antibody-
mediated immune responses.
An explanation for viral promoter attenuation
may be may be the presence of di¡erent transcription
factors present in replicating primary ¢broblasts and
quiescent, implanted ¢broblasts in vivo [32,33]. In
Lf4S and LNC4S gene-transduced ¢broblasts 4S
gene expression was under the transcriptional control
of the viral 5P LTR promoter and CMV immediate^
early promoter, respectively. High levels of 4S activ-
ity were detected in these cells prior to implantation
(Table 2).
The initial, transient levels of 4S activity detected
in peripheral blood leukocytes from cats 241, 244
and 246 may represent 4S expression from im-
planted, dividing ¢broblasts prior to entering a state
of quiescence. In quiescent cells, it is possible that the
transcriptional factors which regulate CMV and
LTR promoter activity are absent [32,33]. Alterna-
tively, the loss of gene expression from ¢broblasts in
vivo may be due to DNA methylation of chromoso-
mal regions within the quiescent cells where retrovi-
ral vectors have integrated in vitro (in cycling cells)
prior to implantation.
The transient nature of 4S gene expression in cats
241, 244 and 246 may also have been due to immune
responses against rf4S and cells expressing rf4S. Due
to the nature of the mutation in the MPS VI cat
colony [2] and from species-speci¢c enzyme replace-
ment studies with rf4S in the MPS VI cat, in which
no immune response was noted (Bielicki et al., in
preparation), we feel it is unlikely that immune re-
sponses were a signi¢cant factor in our experiments.
Indeed, no antibody responses were observed in cats
241, 244 and 246 following implantation of 4S gene-
transduced ¢broblasts.
During the course of this study three kittens died
during the injection of autologous, genetically modi-
¢ed ¢broblasts under the renal capsule (two L476P
homozygous kittens, Table 1, and a L476P hetero-
zygous kitten, result not shown). Despite a detailed
pathological study of these cats, the exact cause of
death was not determined. The implanted, autolo-
gous ¢broblasts may have induced an anaphylactic
response. In subsequent in vivo studies, kittens were
pre-medicated with anti-histamines and were im-
planted with less concentrated, autologous ¢bro-
blasts at an older age. Although these cats survived
surgery, a signi¢cant decrease in heart rate was ob-
served during the injection of cells under the renal
capsule. The results suggest that age, body weight
and the concentration of implanted cells are critical
parameters in determining the outcome of this par-
ticular surgical strategy in cats. Clearly, implanting
cells under the renal capsule of kittens is associated
with a high risk of mortality, which to an extent can
be partially overcome by implanting less concen-
trated cells at an older age.
In summary, this study has highlighted a number
of problems associated with ex vivo-mediated gene
therapy in the MPS VI cat. Firstly, the implantation
of autologous gene-transduced ¢broblasts under the
renal capsule was associated with a signi¢cant risk of
mortality. This problem was overcome in subsequent
operations where less concentrated suspensions of
cells were implanted into cats at an older age. Sec-
ondly, long-term 4S gene expression from ¢broblasts
was not observed in vivo. It is obvious that if ap-
proaches to ex vivo gene therapy are to be success-
fully applied to the MPS, several problems will need
to be addressed. Future work should be aimed to-
ward increasing the long-term survival and level of
therapeutic gene expression from implanted cells in
vivo. This can be done by developing better vectors
which will continue to be expressed at high levels in
vivo, identifying and modulating signals involved in
apoptosis of implanted cells and identifying primary
target cells that have a large proliferative potential
and therefore better long-term survival in vivo.
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